Milestone Scientific Appoints Highly Accomplished MedTech Executive Shanth Thiyagalingam to Board of Directors

Brings Proven Commercial Leadership, Reimbursement Expertise, and Global Market Insight to Support Next Phase of Growth Across Medical and Dental Segments

ROSELAND, N.J., May 19, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that Shanth Thiyagalingam, BMedSc, MMKTG, MBA, has joined its Board of Directors, effective May 14, 2025. Mr. Thiyagalingam brings more than 20 years of global leadership in commercial scaling, product innovation, and strategic execution across the medical device and pharmaceutical industries.

^{Newly appointed board member Shanth Thiyagalingam}

This appointment further supports Milestone Scientific’s strategy to drive adoption of its CompuFlo Epidural System, broaden access under recently assigned favorable Medicare Part B payment rates for CPT code 0777T, and advance commercial initiatives enabled by its Federal Supply Schedule (FSS) contract award.

Neal Goldman, Chairman and Interim CEO of Milestone Scientific, commented:
“We are pleased to welcome Shanth to our Board. His leadership in building and scaling high-growth medical device companies—especially in reimbursement strategy, securing CPT code approval, and commercial execution—makes him an ideal fit as we advance our expansion strategy. His ability to lead cross-functional teams, navigate complex payer environments, and bring novel therapies to market will be invaluable as we pursue broader regional alignment within JMACs, expand our federal presence, and accelerate commercial execution across both our medical and dental verticals.”

Mr. Thiyagalingam currently serves as Chief Executive Officer of PainTEQ, a manufacturer of proprietary medical equipment focused on interventional pain therapy. From 2020 through 2025, he held successive leadership roles at the company—from Chief Commercial Officer to Chief Operating Officer, and ultimately as CEO. During his tenure, he led the company’s transformation from early-stage startup to hyper-growth innovator in the interventional pain space. He also led M&A initiatives and was instrumental in securing a Category 1 CPT code for the LinQ procedure—a new therapy in the interventional pain market. Under his leadership, PainTEQ was recognized three years in a row by the INC 5000 and named a “Best Place to Work” by the Tampa Bay Business Journal.